Business
Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.
May 8, 2025Announcement no. 15 Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained. Interim results and a business update for the first quarter of fiscal 2025 Copenhagen, Denmark, May 8, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced interim financial results for the first three months of 2025 and a business update. Continued progress on key strategic milestones in Q1
About this update from Bioporto A/s
[{"type":"image","alt":"BioPorto A/S","displaySize":"","headline":null,"caption":"BioPorto A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XFhYiV2fxrmNbtDA3N3v_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b7c79bb76fefe5d65277db64dd9691c8","width":300,"height":55}},"lazy":false},{"type":"text","content":"May 8, 2025Announcement no. 15","length":31,"tagName":"p"},{"type":"text","content":" ","length":432,"tagName":"p"},{"type":"text","content":"Continued progress on key strategic milestones in Q1 2025. Total revenue in line with expectations and guidance for 2025 maintained.","length":132,"tagName":"p"},{"type":"text","content":"Interim results and a business update for the first quarter of fiscal 2025","length":74,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, May 8, 2025, (GLOBE NEWSWIRE) – BioPorto A/S (“BioPorto” or the “Company”) (CPH:BIOPOR) today announced interim financial results for the first three months of 2025 and a business update.","length":208,"tagName":"p"},{"type":"text","content":"Continued progress on key strategic milestones in Q1 2025","length":57,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Preparations for the commercial launch of ProNephro AKI NGAL in the U.S. for pediatric use are progressing as expected.","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"The enrollment of patients in the ProNephro AKI (NGAL) study for adult use has been progressing at a faster pace than anticipated. We maintain our goal to submit to the FDA by the end of 2026.","length":192,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":311,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Continued NGAL Research Us...